A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, CROSS-OVER STUDY OF ROSUVASTATIN IN CHILDREN AND ADOLESCENTS (AGED 6 TO <18 YEARS) WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)

HoFH, a rare genetic disorder, results in extremely elevated serum LDL-C, which accumulates in skin, tendons and arteries, often resulting in CVD before age 20, making treatment starting at the time of diagnosis a necessity. Statins are the primary drugs for the treatment of HoFH and have been